APPENDICES. A systematic review and economic model of the ...

Core symptoms Educational performance Quality of life Adverse events
2 children (MPH) discontinued treatment
owing to adverse events. 52% of 155 children
in the MPH group and 38% of 161 children in
the placebo group spontaneously reported
one or more adverse events (p = 0.01)
Teacher scores: MPH MPH
Parent scores: placebo placebo
Appetite loss 42 (27%) 17 (11%)
73 (47%) 33 (20%)
Dull, tired, listless 47 (30%) 45 (28%)
48 (31%) 41 (26%)
Crabby, irritable 34 (22%) 48 (30%)
70 (45%) 79 (49%)
Tearful, sad, depressed 28 (18%) 33 (20%)
44 (28%) 37 (23%)
Worried, anxious 41 (26%) 43 (27%)
36 (23%) 39 (24%)
Motor tics 20 (13%) 26 (16%)
11 (7%) 8 (5%)
Buccal-lingual 17 (11%) 22 (14%)
movements 9 (6%) 7 (4%)
Picking at finger or 32 (21%) 34 (21%)
skin, nail-biting, lip or 37 (24%) 38 (24%)
cheek chewing
Stomach aches 19 (12%) 8 (5%)
36 (23%) 25 (16%)
Headaches 18 (12%) 7 (4%)
33 (21%) 29 (18%)
Trouble sleeping Not Not
evaluated evaluated
50 (32%) 38 (24%)
Not reported Not reported Conners’ Global Index: teacher
MPH: baseline 12.7 (7.24); 3 weeks 4.9 (4.7)
Placebo: baseline 11.5 (7.35); 3 weeks 10.3
(6.9)
MPH > placebo, p < 0.001, 95% CI: 5.26 to
8.09
Conners’ Global Index: parent
MPH: baseline 13.6 (6.6); 3 weeks 7.4 (5.9)
Placebo: baseline 12.9 (7.6); 3 weeks 10.1
(6.7)
MPH > placebo, p < 0.001;
95% CI: 1.7 to 4.9
CGI-Improvement ratings:
CGI efficacy scores in the moderately
improved range or better:
MPH: 64% (98/154)
Placebo: 27% (98/154)
CGI-I Scores:
MPH: 81% (125/154)
Placebo: 50% (78/156)
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 23
No differences between treatments were
found in physical examinations performed at
the end of the treatment period
Conclusions Authors’ conclusions: Modified-release MPH administered once daily in the morning is effective and safe in controlling ADHD
symptoms throughout the day
Reviewer’s comments: No comments noted
269